Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

20071,630 citationsJournal Articlebronze Open Access

Authors

W. Fraser Symmans · Nuvera Biosciences (United States)

Florentia Peintinger · Nuvera Biosciences (United States)

Christos Hatzis · Nuvera Biosciences (United States)

Radhika Rajan · Nuvera Biosciences (United States)

Henry M. Kuerer · Nuvera Biosciences (United States)

Vicente Valero · Nuvera Biosciences (United States)

Lina Assad

Abstract

RCB determined from routine pathologic materials represented the distribution of RD, was a significant predictor of DRFS, and can be used to define categories of near-complete response and chemotherapy resistance.

Topics & Keywords

Breast Cancer Treatment Studies Breast Lesions and Carcinomas Head and Neck Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 25, Issue 28, pp. 4414-4422

DOI: 10.1200/jco.2007.10.6823

Field-Weighted Citation Impact: 14.08